Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: carvedilol Clear all
Completed Phase 3 Interventional Results available

Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure

NCT00624065
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol controlled release/lisinopril, lisinopril + placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
76
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 21, 2026, 5:31 PM EDT
Enrolling by invitation Phase 4 Interventional

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

NCT07298993
View directory record Official record
Conditions
Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Placebo (matching), Beta-blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional Results available

Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF

NCT04757584
View directory record Official record
Conditions
Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure, Heart Disease
Interventions
Beta blockers
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
65 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated Phase 4 Interventional

BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)

NCT00433043
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Beta blocker (carvedilol or metoprolol succinate), CRT (cardiac resynchronization therapy)
Drug · Procedure
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
18 Years to 99 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
New York, New York • Rochester, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 30, 2015 · Synced Oct 21, 2026, 5:31 PM EDT
Not listed Phase 4 Interventional

Rate Control in Atrial Fibrillation

NCT02251509
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Carvedilol, Metoprolol tartrate
Drug
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg

NCT00650416
View directory record Official record
Conditions
Healthy
Interventions
Carvedilol Tablets 12.5 mg, Coreg® Tablets 12.5 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 21, 2026, 5:31 PM EDT
Recruiting Phase 4 Interventional

Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator

NCT06964464
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction (HFrEF), Sudden Cardiac Death, Ventricular Arrhythmia, Implantable Cardioverter Defibrillator (ICD), Beta-blocker Therapy, Cardiomyopathy
Interventions
Metoprolol Succinate, Carvedilol
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
13
States / cities
Scottsdale, Arizona • Rome, Georgia • Shawnee Mission, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 21, 2026, 5:31 PM EDT
Recruiting Phase 3 Interventional

CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

NCT05931276
View directory record Official record
Conditions
End-Stage Kidney Disease, End-Stage Renal Disease
Interventions
Metoprolol Succinate, Carvedilol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Long Beach, California • Aurora, Colorado • West Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated Phase 1 Interventional

Carvedilol PAH A Pilot Study of Efficacy and Safety

NCT02120339
View directory record Official record
Conditions
Pulmonary Hypertension, Cardiac MRI <40
Interventions
Carvedilol
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 12, 2019 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated Not applicable Interventional Results available

Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease

NCT00638222
View directory record Official record
Conditions
Vascular Disease, Kidney Disease
Interventions
Carvedilol and Placebo
Other
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Toledo, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 1 Interventional Results available

Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab

NCT04023110
View directory record Official record
Conditions
Cardiotoxicity, Risk Factor, Cardiovascular, Toxicity Due to Chemotherapy, Breast Cancer, Cardiomyopathies, Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated Phase 2 Interventional Results available

Beta-blockers in Pulmonary Arterial Hypertension

NCT02507011
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Carvedilol, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 21, 2026, 5:31 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Exercise as an Immune Adjuvant for Allogeneic Cell Therapies

NCT06643221
View directory record Official record
Conditions
Leukemia, Hematopoetic Stem Cell Transplantation, Donor Lymphocyte Infusion, CAR T-Cell Therapy, Lymphoma, Cell Therapy
Interventions
Exercise, Isoproterenol, Placebo, Bisoprolol Fumarate Tablet 10 mg, Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Carvedilol 50 mg, Roflumilast 500 Mcg Oral Tablet
Behavioral · Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2031
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated Phase 2 Interventional

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy

NCT06844669
View directory record Official record
Conditions
HER2-positive Breast Cancer, HER2+ Breast Cancer
Interventions
Carvedilol, Empagliflozin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 5:31 PM EDT
Not listed Phase 4 Interventional

Coreg CR, Blood Vessel Stiffness and Blood Vessel Function

NCT00732511
View directory record Official record
Conditions
Endothelial Function, Diabetes Mellitus, Hypertension
Interventions
carvedilol, metoprolol extended release
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2011 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated No phase listed Observational

Retrospective Evaluation of Carvedilol Versus Captopril in CHF Patients

NCT00249067
View directory record Official record
Conditions
Heart Failure, Heart Murmurs
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2007 · Synced Oct 21, 2026, 5:31 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.

NCT00524134
View directory record Official record
Conditions
Epilepsy
Interventions
Carvedilol-CR
Drug
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 21, 2026, 5:31 PM EDT
Withdrawn Phase 3 Interventional

Mechanism of Masked Hypertension - Intervention

NCT04121299
View directory record Official record
Conditions
Masked Hypertension
Interventions
Carvedilol, Amlodipine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 21, 2026, 5:31 PM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 2 Interventional Results available

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

NCT01009918
View directory record Official record
Conditions
Breast Cancer, Cardiac Toxicity
Interventions
Coreg CR®, lisinopril, placebo
Drug · Other
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
174
States / cities
Long Beach, California • Sylmar, California • Aurora, Colorado + 142 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional

Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD

NCT03370835
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Asthma, Adverse Effect of Beta-adrenoreceptor Antagonists
Interventions
Metoprolol succinate ER, Carvedilol
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
40 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Not applicable Interventional Results available

Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial

NCT00578617
View directory record Official record
Conditions
Atrial Fibrillation, Arrhythmia
Interventions
Rate Control, Ablation Therapy, Rhythm control
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
10
States / cities
Birminham, Alabama • Los Angeles, California • Maywood, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 21, 2026, 5:31 PM EDT
Completed Phase 4 Interventional

Effects of Carvedilol on Health Outcomes in Heart Failure

NCT00381030
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
carvedilol plus nurse management
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
0 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 27, 2006 · Synced Oct 21, 2026, 5:31 PM EDT